

## DAFTAR PUSTAKA

1. Trisnohadi HB. Perkembangan terbaru penatalaksanaan sindrom koroner akut. Dalam: Setiati S, Alwi I, Kasjmir YI, et al., eds. *Current diagnosis and treatment In Intenal medicine*. 1 ed: Pusat informasi dan penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia; 2002:205-208.
2. Suryadipraja M. Upaya mengendalikan faktor-faktor resiko tradisional dan yang baru pada penyakit jantung koroner. Dalam: Setiati S, Alwi I, Kasjmir YI, et al., eds. *Current diagnosis and treatment In Intenal medicine*. 1 ed: Pusat informasi dan penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia; 2002:233 -237.
3. Pischeda T, Girman C, Hotamisligil GS. Plasma Adiponectin Levels and Risk of Myocardial Infarction in Men. *JAMA*. 2004;291:1731-1737.
4. Ross R. Atherosclerosis: an inflammatory disease. *N Engl J Med*. 1999;340:115-126.
5. Lawrence G. sindrom metabolik merupakan manifestasi dari keadaan inflamasi. *J Med Nus*. 2005;26:48-57.
6. Funahashi T, Hotta K, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectine, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol*. 2000;20:1595-1599.
7. Kumada M, Kihara S, Sumitsuji S. Association of Hypoadiponectinemia with Coronary Artery Disease in Men. *Arterioscler Thromb Vasc Biol* 2003;23:85-89.
8. Chadrana M, Susan P, Chiaraldhi T, et al. Adiponectin: More than just another fat cell hormone. *Diab care*. 2003;26:2442 -2449.
9. Bukhari M. Diabetes miltus tipe 2 sebagai penyakit inflamasi. *J Med Nus*. 2007;28:42-50.
10. Bloomgarden T. Definition of the insulin resistance syndrome. *Diab care*. 2004;27:824 -830.
11. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptor. *Endocr Rev*. 2005;26:439 -451.
12. Shimomura I, Matsuzawa Y. Hypoadiponectinemia associates with insulin resistant syndrome. In: Medeiros-Naio G, Halpern A, Bouchard C, eds. *Progress in obesity research*. Vol 40; 2003:193 -196.
13. Ogawa Y, Kikuchi T, Nagasaki K. Usefullnes of serum adiponectin level as diagnostic marker of metabolic syndrome in obese Japanese children. *Hypertens Res*. 2005;28:51 -57.
14. Maytin M, Leopold J, Loscalzo J. Oxidant stress in the vasculature. *Curr Atheroscler Rep*. 1999;1:156-164.
15. Fasshauer M, Paschke R, Stumvoll M. Adiponectin, Obesity, and cardiovascular disease. *Biochimie*. 2004;86:779-784.
16. Adam J. Obesitas, pengertian dan kriteria diagnosis. In: Adam J, ed. *Obesitas dan sindrom metabolik*. Bandung; 2006.
17. Popma J, Bittl J. Anatomy and variation of the coronary arteries. In: Giziano J., *Coronary angiography and intravascular ultrasonography*. *Heart Disease*. Vol 12; 2001:387-419.
18. Fruebis J, Tsao T, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increase fatty acid oxidation

- in muscle and causes weight loss in mice. *Proc. Natl. Acad. Sci USA.* 2001;98:2005-2010.
19. Adi S. Sel lemak dan fungsi endokrin. In: Adam J, ed. *Obesitas dan Metabolik sindrome*. Bandung; 2006:43-59.
  20. Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and Metabolic Syndrome. *Arterioscler Thromb Vasc Biol.* 2004;29:33.
  21. J. Fan, T. Watanabe. Inflammatory reactions in the pathogenesis of atherosclerosis. *J Atheroscler Thromb.* 2003;10:63-71.
  22. Goldstein B, Scalia R. Adiponectin: A Novel adipokine linking adipocytes and vascular function. *J Clin Endocrinol Met.* 2004;89:2563 -2568.
  23. Krakoff J, Funahashi T, Stehouwer D. Inflamatory Marker, adiponectin, and risk of type 2 diabetes in Pima Indian. *Diab care.* 2003;26:1745-1751.
  24. Reider R. The metabolic syndrome. More than the sum of its parts? *Circulation.* 2003;108:1546 -1551.
  25. Kim C, Lee WJ. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. *J Clin Endocrinol Met.* 2004;24:75-80.
  26. Yoo T, Sung S. Relationships between serum uric acid concentration and insulin resistance and metabolic syndrome. *Circulation.* 2005;69:928-933.
  27. Skorecki K, Green J, Brenner BM. Chronic renal failure. In: Kasper DL, Fauci AS, Braunwald E, et al., eds. *Harrison's Principles of internal medicine*. Vol 261. 16 ed. Mc Graw Hill New York; 2005:1653 -1663.
  28. Baim DS. Percutaneous Coronary Revascularization. In: Kasper DL, Fauci AS, Braunwald E, et al., eds. *Harrison's Principles of internal medicine*. Vol 229. 16 ed. Mc Graw Hill New York; 2005:1459 -1462.
  29. Franch RH, Spencer S, smith J. Technique of cardiac catheterization including coronary arteriography. In: Giziano J., eds. Diagnostic technique of cardiac catheterization and vascular angiography. *The Heart.* Vol 21. 3 ed. New York; 2004:2381-2418.
  30. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complication. In: consultation RoW, ed. Genewa: World Health Organization; 1999.
  31. JNC 7. Seventh Report of the joint National Committee on Prevention, Detection, Evaluation, and treatment of high blood pressure. The JNC 7 Report. *JAMA.* 2003;289:2560-2572.
  32. Gaziano T. Screening for Coronary heart Disease and ats risk factor. In: Saunders P, ed. *Braunwald's Primary Cardiology 2<sup>nd</sup>*. USA; 2003:261-276.
  33. Inoue K, ZimmetP. The Asia Pasific Perspective: Redefining Obesity and its Treatment. *Health communications australia* . Australia; 2000:235 -239.
  34. Szmitko P, Wang C, Weisel R, et al. New markers of inflammation and endothelial cell activation. *Circulation.* 2003;108:1917-1923.
  35. Iglseder B , Vitold M, Stadlmayer A, et al. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis. *Am Heart Assoc.* 2005;36:2577 -2582.
  36. Lindsay RS, Resnick HE, Zhu J, et al. Adiponectin and coronary heart disease: The Strong Heart Study. *Arterioscler Thromb Vasc Biol.* 2005;25:15-16.
  37. Lindsay R, Resnick H, Ruotolo G. Adiponectine, relationship to proteinuria but not coronary heart diasease: the Strong Heart Study. *Diabetes.* 2003;52:161A.

38. Combs JA, Wagner J, Berger T, et al. Induction of adipocyte complement-related protein of 30 KDa by PPARgamma agonists: a potential mechanism of insulin sensitization. *Endocrinology*. 2002;143:998-1007.
39. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. *Circ. Res.* 2005;96:939-949.
40. Ismaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care*. 2001;24:683-689.
41. Ridker P, Buring J, Cook N, et al. C-Reactive Protein, the metabolic syndrome and risk incident cardiovascular events. *Circulation*. 2003;107:391-397.
42. Sattar N, Gaw A, Schebakova O, et al. Metabolic syndrome with and without C-reactive Protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. *Circulation*. 2003;108:414-419.

## LAMPIRAN I

### FORMULIR PENELITIAN

#### HUBUNGAN KADAR ADIPONEKTIN DENGAN JUMLAH ARTERI KORONER YANG MENGALAMI PENYEMPITAN PADA PENDERITA PJK

---

Nama	:			(L/P)
Umur	:	Tahun	Agama:	
Suku	:			
Pekerjaan	:			
Alamat/No. Telpon :				
Tanggal angiografi :		Angiografi sebelumnya:.....		

---

#### I. Anamnesis

##### a. Riwayat penyakit yang pernah diderita:

Diabetes mellitus	(tidak / ya)
Tekanan darah tinggi	(tidak / ya)
Penyakit jantung	(tidak / ya)
Dislipidemia	(tidak / ya)

##### . Riwayat penyakit dalam keluarga :

Kegemukan	Tidak / Ya, siapa .....
Diabetes mellitus	Tidak / Ya, siapa .....
Penyakit jantung	Tidak / Ya, siapa .....
Infark miokard sebelumnya	Tidak / ya .....
Tekanan darah tinggi	Tidak / Ya, siapa .....
Dislipidemia	Tidak / Ya, siapa .....
Rokok	Tidak/ya, jumlah....btg/hr.

b. Pengobatan/diet yang sedang dijalani: Tidak Ada/ya.....

c. Olahraga/aktivitas fisik: .....

Frekuensi ..... kali/minggu, lamanya .....jam

#### II. Pemeriksaan Fisik

Tinggi badan :..... cm	Berat badan :..... kg
IMT :..... kg/m <sup>2</sup>	
Tekanan darah:.....mmHg	Denyut jantung :..... /menit

#### III. Hasil Laboratorium

GDP :.....	Kolesterol total:.....
Kol-HDL :.....	Kolesterol LDL:.....
Trigliserida :.....	Asam urat :.....
Hemoglobin :.....	Kreatinin :.....
Hematokrit :.....	
Adiponektin :.....	

#### IV. EKG :.....

Foto Thorak :.....

Echocardiografi :.....

Kateterisasi jantung :.....

## LAMPIRAN II

### **PERNYATAAN PERSETUJUAN**

Yang bertanda tangan di bawah ini :

Nama : .....

Alamat : .....

Menyatakan bersedia untuk berpartisipasi pada penelitian ini, yaitu

**” HUBUNGAN KADAR ADIPONEKTIN DENGAN BANYAKNYA ARTERI KORONER YANG MENGALAMI STENOSIS PADA PENDERITA PENYAKIT JANTUNG KORONER”** setelah mendapatkan penjelasan dan manfaatnya bagi ilmu kedokteran.

Makassar, .....

Peneliti,

Yang membuat persetujuan,

Dr. I Made Duwi Sumohadi .....  
.....